Day: April 1, 2024

Reports acceleration of reimbursement claims submission for the CompuFlo® Epidural System Technology ROSELAND, N.J., April 01, 2024 (GLOBE NEWSWIRE) — Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today provides a business update and announces financial results for the year ending December 31, 2023. Arjan Haverhals, CEO and President of Milestone Scientific, stated, “We achieved solid financial results in 2023, with revenue increasing 11.6% and gross profit increasing 39%. We attribute this performance to the success of our new online sales portal for the STA Single Tooth Anesthesia System® (STA) in the U.S., which has enhanced our margins, while providing us a closer relationship with our dental customers. While this was a transitional...

TORONTO, April 01, 2024 (GLOBE NEWSWIRE) — Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced financial results for the three and twelve months ended December 31, 2023. Fourth Quarter and Fiscal Year 2023 Summary & Recent Progress:Company continues to execute against Transformational Plan and achieved primary objective of reducing cash burn by over 50% vs. prior yearCash used in operations for fiscal year 2023 of $12.9 million, down 52% year-over-year, from $27.0 million in the prior year period Cash system revenue for fiscal year 2023 represented approximately 67% of total systems and subscriptions revenue, compared to 58% in the prior year periodMacroeconomic headwinds and accelerated restructuring in international markets resulted in softer-than-expected...

Received IDE approval for the Revita® Remain-1 pivotal study for weight maintenance in patients with obesity after discontinuation of GLP-1 Based Drugs Completion of enrollment in pivotal Revitalize-1 study in patients with inadequately controlled T2D expected in second quarter of 2024 and anticipated topline data in fourth quarter of 2024 Announced nomination of RJVA-001 as first clinical candidate in the Rejuva® GLP-1 gene therapy platform; completion of IND-enabling studies expected in second half of 2024 Completed initial public offering of common stock raising $110 million in gross proceeds; cash on hand expected to fund operations through 2025 BURLINGTON, Mass., April 01, 2024 (GLOBE NEWSWIRE) — Fractyl Health (Nasdaq: GUTS), a metabolic therapeutics company focused on pioneering new approaches for the treatment of type 2...

32.8% Year-Over-Year Revenue Growth for Fourth Quarter of 2023 Gross Profit Increases 125.8% in 2023 with Gross Margin Increasing by 270 Basis Points Edible Garden Secures Two New Patents in 2024 Highlighting Company’s Innovation Leadership Position in AgTech; Driving Efficiency and Expected Profitability Conference Call to Be Held Today at 8:00 am ET. BELVIDERE, N.J., April 01, 2024 (GLOBE NEWSWIRE) — Edible Garden AG Incorporated (“Edible Garden” or the “Company”) (Nasdaq: EDBL), a leader in controlled environment agriculture (CEA), locally grown, organic and sustainable produce and products, today provided a business update and reported financial results for the three month and full year periods ended December 31, 2023. Mr. Jim Kras, Chief Executive Officer of Edible Garden, commented, “We are extremely pleased to report a 21.6%...

Revenues Increase, While Rising Interest Rates and Commercial Real Estate Values Impact Earnings Company to Host Webcast and Conference Call BRANFORD, Conn., April 01, 2024 (GLOBE NEWSWIRE) — Sachem Capital Corp. (NYSE American: SACH) announced its financial results for the year ended December 31, 2023. The Company will host a conference call on Monday, April 1, 2024 at 8:00 a.m. Eastern Time to discuss its financial and operating results. John Villano, CPA, Sachem Capital’s Chief Executive Officer commented, “While we remained disciplined and focused as we grew 2023 revenue nearly 26% over the prior year, we were met with a difficult macroeconomic backdrop including rising interest rates, weakness in commercial real estate, specifically office, and banking sector challenges. As a result, changes in the values of certain commercial...

Establishes Full Year 2024 Revenue Guidance of $112 Million – $116 Million BELGRADE, Mont., April 01, 2024 (GLOBE NEWSWIRE) — Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the fourth quarter and year ended December 31, 2023. “2023 was a transformative year for Xtant Medical. We achieved record annual revenues of $91.3 million, up 58% year-over-year, on which we generated organic growth of 15% compared to the prior year,” said Sean Browne, President and CEO of Xtant Medical. “Additionally, we successfully integrated three separate businesses that are integral to our growth platform. From a profitability perspective, we increased our annual gross margin by 540 basis...

TRV045, novel S1P receptor modulator for chronic pain and epilepsy, advances toward important milestones in both non-clinical and clinical studies Company announces reduction of OLINVYK commercial support and review of alternatives for OLINVYK CHESTERBROOK, Pa., April 01, 2024 (GLOBE NEWSWIRE) — Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today reported its financial results for the fourth quarter ended December 31, 2023 and provided an overview of its recent operational highlights. “Despite OLINVYK’s differentiated profile, the hospital environment continues to be challenging. Given performance to date, we are reducing commercial support and reviewing alternatives for OLINVYK to preserve...